Log in

NASDAQ:INMBINmune Bio Stock Price, Forecast & News

-0.49 (-4.81 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $9.69
50-Day Range
MA: $9.50
52-Week Range
Now: $9.69
Volume317,250 shs
Average Volume451,072 shs
Market Capitalization$130.31 million
P/E RatioN/A
Dividend YieldN/A
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:INMB



Sales & Book Value

Annual SalesN/A
Book Value$2.19 per share


Net Income$-7,680,000.00


Market Cap$130.31 million
Next Earnings Date11/13/2020 (Estimated)
OptionableNot Optionable
-0.49 (-4.81 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INMB News and Ratings via Email

Sign-up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

INmune Bio (NASDAQ:INMB) Frequently Asked Questions

How has INmune Bio's stock been impacted by Coronavirus (COVID-19)?

INmune Bio's stock was trading at $4.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INMB shares have increased by 101.9% and is now trading at $9.69.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of INmune Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for INmune Bio

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for INmune Bio

How were INmune Bio's earnings last quarter?

INmune Bio Inc (NASDAQ:INMB) issued its earnings results on Wednesday, August, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.20).
View INmune Bio's earnings history

What price target have analysts set for INMB?

3 brokers have issued twelve-month price targets for INmune Bio's shares. Their forecasts range from $13.00 to $26.00. On average, they anticipate INmune Bio's stock price to reach $19.67 in the next year. This suggests a possible upside of 103.0% from the stock's current price.
View analysts' price targets for INmune Bio

Has INmune Bio been receiving favorable news coverage?

Media headlines about INMB stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. INmune Bio earned a daily sentiment score of -2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about INmune Bio

Are investors shorting INmune Bio?

INmune Bio saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 7,400 shares, an increase of 48.0% from the May 31st total of 5,000 shares. Based on an average trading volume of 37,900 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold.
View INmune Bio's Short Interest

Who are some of INmune Bio's key competitors?

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), salesforce.com (CRM), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and NVIDIA (NVDA).

Who are INmune Bio's key executives?

INmune Bio's management team includes the following people:
  • Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO & Director (Age 63)
  • Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 49)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer (Age 56)

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Financial Advocates Investment Management (1.75%). Company insiders that own INmune Bio stock include David J Moss, Linda F Powers, Mark William Lowdell, Raymond Joseph Tesi and Scott Juda.
View institutional ownership trends for INmune Bio

Which institutional investors are selling INmune Bio stock?

INMB stock was sold by a variety of institutional investors in the last quarter, including Financial Advocates Investment Management.
View insider buying and selling activity for INmune Bio

How do I buy shares of INmune Bio?

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $9.69.

How big of a company is INmune Bio?

INmune Bio has a market capitalization of $130.31 million. The company earns $-7,680,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. INmune Bio employs 3 workers across the globe.

What is INmune Bio's official website?

The official website for INmune Bio is www.inmunebio.com.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.